What is Nolpaza 40 mg tabletki dojelitowe used for?

Pantoprazole is indicated for use in adults and adolescents 12 years of age and above for: • Symptomatic gastro-oesophageal reflux disease. • long-term management and prevention of relapse in reflux oesophagitis. For long-term management and prevention of relapse in reflux oesophagitis. Pantoprazole is indicated for use in adults for: • Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAID

What pharmaceutical form is Nolpaza 40 mg tabletki dojelitowe available in?

Nolpaza 40 mg tabletki dojelitowe: Tabletki dojelitowe 40 mg

What are the side effects of Nolpaza 40 mg tabletki dojelitowe?

Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). For all adverse reactions reported from post-marketing experience, it is not possible to apply any A

Who should NOT take Nolpaza 40 mg tabletki dojelitowe?

Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients listed in section 6.1.

Does Nolpaza 40 mg tabletki dojelitowe interact with other medications?

Medicinal products with pH-Dependent Absorption Pharmacokinetics Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with the absorption of medicinal products where gastric is an important determinant of oral bioavailability e.g. some azole antifungals such as ketoconazole, itraconazole, posaconazole and other medicines such as erlotinib. HIV protease inhibitors Co-administration of pantoprazole is not recommended with HIV protease inhibitors for

Can Nolpaza 40 mg tabletki dojelitowe be used during pregnancy?

Pregnancy A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of Pantoprazole. Animal studies have shown reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Pantoprazole during pregnancy. Breast-feeding Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretio

What precautions should be taken with Nolpaza 40 mg tabletki dojelitowe?

Any unused product or waste material should be disposed of in accordance with local requirements.

What ATC class does Nolpaza 40 mg tabletki dojelitowe belong to?

Nolpaza 40 mg tabletki dojelitowe: ATC A02BC02. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Nolpaza 40 mg tabletki dojelitowe

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Nolpaza 40 mg tabletki dojelitowe — Description, Dosage, Side Effects | PillsCard

Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC02 Mechanism of action Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells. Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously. Pharmacodynamic effects The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long- term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans. An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies. During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

Nolpaza 40 mg tabletki dojelitowe

User Reviews